Best Oral Session

Best Oral Session 1

· Room: 501 December 4th 08:30-09:30 ·

Time	Abstract ID	Title	Presenting Author	Country/Region
08:30-08:38	ASGO20260196	Patient-derived organoid screening reveals penfluridol targeting of dopamine receptor type 2 in small cell carcinoma of the cervix	Bai Hu	China mainland
08:38-08:46	ASGO20260513	Tumor-educated platelet transcripts with the routine blood count outperform cancer antigen 125 for ovarian cancer detection, particularly in premenopausal women	Se Ik Kim	Korea
08:46-08:54	ASGO20260432	Pembrolizumab or placebo plus concurrent chemoradiotherapy for newly diagnosed, high-risk, locally advanced cervical cancer: final analysis results from ENGOT-cx11/GOG-3047/KEYNOTE-A18 in participants enrolled in East Asia	Yang Xiang	China mainland
08:54-09:02	ASGO20260093	Bicenter noninvasive identification of p53abn EC by integrating MRI-derived spatial microenvironmental features	Wenxiu Guo	China mainland
09:02-09:10	ASGO20260380	Association of omentectomy with reduced therapeutic efficacy of lenvatinib plus pembrolizumab in patients with endometrial cancer	Rintaro Hamada	Japan
09:10-09:18	ASGO20260502	AI-assisted personalized decision-making models for timing of surgery in advanced ovarian cancer	Xin Zhen	China mainland
09:18-09:30		Q&A		

Best Oral Session 2

· Room: Hall B December 5th 10:55-11:55 ·

Time	Abstract ID	Title	Presenting Author	Country/Region
10:55-11:03	ASGO20260221	Disease prognostication by clinico-radiomics signatures in ovarian clear cell carcinoma	Elaine Lee	Hongkong, SAR, China
11:03-11:11	ASGO20260569	Impact of the first-line PARP inhibitor maintenance on platinum sensitivity and proteomic profiles in recurrent ovarian cancer	Xiaodong Cheng	China mainland
11:11-11:19	ASGO20260100	A multiplexed genome engineering and single-cell framework reveals KrasG12D evolutionary traits in ovarian cancer	Wutao Chen	China mainland
11:19-11:27	ASGO20260426	Trastuzumab deruxtecan plus bevacizumab as first-line maintenance therapy for human epidermal growth factor receptor 2-expressing ovarian cancer: Safety run-in results from DESTINY-Ovarian01	Kasumi Yamamoto	Japan
11:27-11:35	ASGO20260652	Response-independent overall survival benefit in the phase 3 ROSELLA Trial (APGOT-Ov10) of relacorilant plus nab-paclitaxel vs nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer	Jae-Weon Kim	Korea
11:35-11:43	ASGO20260204	Combined analysis of a novel articulated laparoscopic camera system in minimally invasive gynecologic surgery across two prospective studies	Tong Yow Ng	Hong Kong, SAR, China
11:43-11:55		Q&A		